Top-News

Global Blood Therapeutics News

Keine aktuellen Kursdaten verfügbar
WKN: A14YE6
ISIN: US37890U1088
US-Symbol: GBT
Typ: Aktie

Global Blood Therapeutics News

08.08.22 - PR Newswire
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE PR Newswire
08.08.22 - PR Newswire
Thinking about buying stock in Palantir Technologies, Carnival Corp, Robinhood Markets, Global Blood Therapeutics, or Tilray?
Thinking about buying stock in Palantir Technologies, Carnival Corp, Robinhood Markets, Global Blood Therapeutics, or Tilray? PR Newswire
08.08.22 - Der Aktionär
Pfizer: Heiße Übernahmegerüchte
04.08.22 - PR Newswire
Thinking about buying stock in Exicure, Yellow Corp, Senseonics, Global Blood Therapeutics, or Motus GI?
Thinking about buying stock in Exicure, Yellow Corp, Senseonics, Global Blood Therapeutics, or Motus GI? PR Newswire
26.07.22 - GlobeNewswire
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease
13.06.22 - GlobeNewswire
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
Sickle Cell Health Awareness, Perspectives and Experiences (SHAPE) survey developed with international steering committee of medical experts and patient advocates
10.06.22 - GlobeNewswire
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year
16.02.22 - GlobeNewswire
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term ...
27.01.22 - GlobeNewswire
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics (GBT) today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) ...
17.12.21 - GlobeNewswire
GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
European Commission decision on marketing authorization anticipated first quarter of 2022
14.09.21 - GlobeNewswire
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the launch of The GBT Foundation, a ...
14.09.21 - GlobeNewswire
GBT ruft Stiftung ins Leben mit dem Ziel, benachteiligten Patientengruppen weltweit eine bessere Versorgung und Unterstützung zu ermöglichen
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat die Gründung der GBT Foundation bekannt ...
14.06.21 - GlobeNewswire
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company ...
11.06.21 - GlobeNewswire
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
11.06.21 - GlobeNewswire
Neue Belege für die potenzielle Anwendung von Oxbryta® (voxelotor) bei Kindern mit Sichelzellkrankheit im Alter von 4 bis 11 Jahren auf dem virtuellen Kongress der European Hematology Association 2021 vorgestellt
Analyse der Phase-2a-Studie HOPE-KIDS 1 in oraler Präsentation vorgestellt
12.05.21 - GlobeNewswire
GBT kündigt Präsentation von Daten auf dem virtuellen Kongress der European Hematology Association (EHA) 2021 an
Neue Daten zu Oxbryta® (Voxelotor) aus der Phase-​IIa-Studie HOPE-KIDS 1 zeigen Verbesserung hinsichtlich Hämoglobin und Hämolyse bei Kindern mit Sichelzellkrankheit im ...
12.05.21 - GlobeNewswire
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease
09.04.21 - GlobeNewswire
Vollständige Ergebnisse nach 72 Wochen der Phase-3-HOPE-Studie zu Oxbryta® (Voxelotor) Tabletten in The Lancet Haematology veröffentlicht – signifikante Verbesserung von Hämoglobin, Hämolyse und der allgemeinen Gesundheit bei Patienten mit Sichelzellkrankheit
SOUTH SAN FRANCISCO, Kalifornien, April 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat heute bekanntgegeben, dass The Lancet ...
08.04.21 - GlobeNewswire
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has ...
27.01.21 - GlobeNewswire
Europäische Arzneimittelagentur genehmigt GBTs Antrag auf Marktzulassung für Oxbryta® (Voxelotor) zur Behandlung hämolytischer Anämie bei Sichelzellkrankheit
SOUTH SAN FRANCISCO, Kalifornien, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) hat heute bekanntgegeben, dass die ...

Newssuche

Videos

newspaper
26.04.24 +10,71%
Technical Trading: Gold Long freitags
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »